14results about How to "Maintain steady state" patented technology

The invention discloses lactobacillus reuteri CCFM1288 for relieving depressive mood and application of the lactobacillus reuteri CCFM1288, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1288 has the tryptophan metabolism capability, and can survive for 7 days in the intestinal tract; after the lactobacillus reuteri CCFM1288 intervenes a depressive mouse, anxiety-like and depression-like behaviors of the mouse can be obviously relieved, flora alpha-diversity is improved, intestinal symbiotic bacteria are promoted to secrete indole substances, intestinal homeostasis is maintained, hypothalamic-pituitary-adrenal axis hyperfunction is relieved, dopamine and serotonin neurotransmitter nervous system functions are improved, and the effect of preventing and treating depression is achieved. The neurotransmitter release is promoted, and the anti-depression effect is achieved. In clinical tests, intervention of Lactobacillus reuteri CCFM1288 can significantly improve the depressive symptom of MDD patients, and a new safe alleviation approach is provided for depression treatment.

The invention discloses application of enterococcus pluvialis and exosomes thereof, and relates to the field of application of enterococcus pluvialis and exosomes thereof. The enterococcus pluvialis disclosed by the invention is enterococcus pluvialis Zz-2024, is preserved in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms, and has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 31249. The invention relates to an exosome produced by Enterococcus pluvialis Zz-2024, and an application of the exosome in a medicine for treating myocarditis, and particularly relates to an exosome produced by Enterococcus pluvialis Zz-2024 and an application of the exosome in a medicine for treating myocarditis. The enterococcus pluvialis exosome disclosed by the invention has excellent effects in experiments of inhibiting myocarditis factors, reducing lipid droplet aggregation, inhibiting myocardial cell senescence and the like, and breaks through the limitation that human stem cell source exosomes are adopted in related fields at present.

The invention belongs to the technical field of biological medicines, discloses application of bifidobacterium breve BB990 in the field of metabolism, and particularly discloses bifidobacterium breve BB990 which is preserved in Guangdong Microorganism Culture Collection Center, the preservation number is GDMCC No.63259, and the preservation date is March 10, 2023. The invention further discloses a preparation method of the bifidobacterium breve BB990. The bifidobacterium breve BB990 provided by the invention has the effects of regulating gastrointestinal disorder, enhancing intestinal immune function, inhibiting harmful bacteria, improving intestinal flora structure, maintaining intestinal steady state, regulating immunity, improving immune curative effect, regulating body glycometabolism and liver metabolism and the like. Experiments prove that the bifidobacterium breve BB990 can effectively prevent and treat metabolic diseases, such as non-alcoholic fatty liver, type II diabetes and the like, the treatment effect of the bifidobacterium breve BB990 is remarkably superior to that of other bifidobacterium breve (such as bifidobacterium breve 206), and the bifidobacterium breve BB990 has a good prospect.

The invention discloses bifidobacterium longum subsp. Infantis i18 with an effect of regulating intestinal flora and application of the bifidobacterium longum subsp. Infantis i18, and belongs to the technical field of microbial engineering. The bifidobacterium longum subsp. Infantis i18 strain is preserved in the China General Microbiological Culture Collection Center, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation date is July 25, 2024, the preservation number is CGMCC NO.31411, and the Latin name is Bifidobacterium longum subsp. Infantis. The invention also discloses a preparation method of the bifidobacterium longum subsp. Infantis strain. The bifidobacterium longum subsp. Infantis i18 provided by the invention has a bidirectional regulation effect, can relax bowel, relieve diarrhea, maintain intestinal steady state and regulate intestinal flora at the same time, expands the application range of the bifidobacterium longum subsp. Infantis, and enriches the types of the domestic bifidobacterium longum subsp. Infantis. The preparation method is suitable for preparing the probiotic agent or the infant formula milk powder.

The present invention proposes a fermentation anti-hair loss composition and a preparation method thereof, and belongs to the technical field of hair care products. Wheat protein / biotin-ornithine / nicotinamide condensation complex is prepared by dehydration condensation, Zn ions are chelated to obtain chelated zinc complex, tea polysaccharide is extracted, and licorice, astragalus, ginger, and ginseng are extracted by ethanol aqueous solution to obtain extract, tea residues and solid residues are fermented by lactic acid bacteria to obtain fermentation products, and fermentation products, tea polysaccharides, extracts, chelated zinc complexes, oleanolic acid, pantothenic acid, and hydroxyethylpiperazineethanesulfonic acid are mixed uniformly to obtain a fermentation anti-hair loss composition. The fermentation anti-hair loss composition prepared by the present invention has good antioxidant, antibacterial, mite removal, and anti-inflammatory effects, protects scalp health and maintains scalp homeostasis, promotes hair growth, reduces the effect of hair loss, improves the toughness and elasticity of hair, nourishes hair, has good anti-hair loss and solid hair growth effects, and has broad application prospects.

The present invention belongs to the field of biomedicine technology. Specifically, it relates to the use of Fam3a inhibitors in the preparation of drugs that promote GLP-1 secretion in pancreatic alpha cells and regulate systemic glucose homeostasis. The research results of the present invention show that Fam3a in pancreatic alpha cells changes the body's glucose homeostasis by regulating the GLP-1 paracrine signaling pathway, that is, the specific lack of Fam3a in pancreatic alpha cells can promote the production of pancreatic GLP-1, which acts on adjacent β cells in a paracrine form to promote insulin secretion and maintain systemic glucose homeostasis. The present invention clarifies for the first time the role and specific mechanism of Fam3a in pancreatic alpha cells, and provides a new targeted treatment option for promoting pancreatic GLP-1 secretion, which has extremely high application value and social benefits.

The application discloses a DNA sulfur-modified bacillus subtilis and application thereof in alleviating alcoholic diseases, and relates to the field of biochemistry.The application provides a DNA sulfur-modified bacillus subtilis, which is named as Bacillus subtilis E10-1 and has a preservation number of CCTCC NO: M20253036.It is verified through animal experiments that the DNA sulfur-modified bacillus subtilis E10-1 is more resistant to alcohol than a strain in which sulfur modification is knocked out, can reduce the levels of indexes such as glutathione pyrotransaminase, glutathione transaminase and urea nitrogen in serum of a host after drinking alcohol, and the level of interferon gamma, can increase the levels of total protein, superoxide dismutase and glutathione peroxidase, can alleviate oxidative stress damage caused by alcohol, can reduce inflammatory reactions of various organ tissues, can maintain normal physiological functions of cells, can repair intestinal barriers, and can maintain intestinal flora homeostasis, so that alcoholic related diseases can be prevented and / or treated.

This invention belongs to the field of microbial technology, specifically relating to a strain of *Lactobacillus vaginalis* 244 and its applications. The *Lactobacillus vaginalis* described in this invention... Limosilactobacillus vaginal Lactobacillus vaginis 244 was deposited at the Guangdong Provincial Center for Microbial Culture Collection on May 22, 2026, with accession number GDMCC No: 68333. Lactobacillus vaginis 244 exhibits good antibacterial, stress-resistant, and acid- and bile-salt-resistant properties, and can colonize the intestines. Furthermore, Lactobacillus vaginis 244 can enhance the resistance of piglets to PEDV infection, promote piglet growth, and alleviate clinical symptoms caused by PEDV infection. The Lactobacillus vaginis 244 provided by this invention offers a novel intervention target and control strategy for PEDV infection.

This invention provides a rumen methane inhibitor and its application, belonging to the field of ruminant farming. The active ingredients of the rumen methane inhibitor of this invention include: *Lactobacillus reuteri* inoculum, *Lactobacillus gasseri* inoculum, *Lactobacillus casei* inoculum, amylase, phytase, xylanase, cellulase, and β-glucanase. The rumen methane inhibitor can effectively regulate the intestinal microbiota of dairy cows, promote the decomposition of fibrous material in the rumen, optimize the rumen fermentation environment, thereby controlling rumen function, reducing methane production, and improving the productivity of ruminants. The rumen methane inhibitor is safe and environmentally friendly, which is conducive to its application in ruminant farming, agriculture, and other fields, and has good practicality.

The application provides application of adamantane derivatives in preparation of drugs for preventing or treating lung diseases. In a LPS-induced neonatal rabbit ARDS model, early intervention of adamantane derivative-011 helps to improve neuromotor impairment of animals, relieve acidosis, improve oxygenation, significantly improve lung pathological damage, restore phospholipid dysfunction and synthesis disorder, and maintain the homeostasis of lung surfactant. The results of transcriptome sequencing and RT-PCR also prove that the intervention of adamantane derivative-011 can significantly down-regulate the gene expression of multiple inflammatory signaling pathways of lung tissues caused by LPS, especially the mRNA expression of key genes of the TLR-NF-kB signaling pathway.

The present invention relates to the field of microbial technology. The present invention provides an Enterococcus hirae QT4713, whose taxonomic name is Enterococcus hirae, which was deposited in the China Center for Type Culture Collection on December 11, 2023, and the deposit address is Wuhan University, Wuhan, China, and the deposit number is CCTCC NO: M20232523. The present invention also provides a microbial agent comprising the Enterococcus hirae QT4713 strain and its application, which has a strong prebiotic function unique to plateau lactic acid bacteria, as well as strong anti-inflammatory ability, gastrointestinal fluid tolerance and safety, and can better alleviate DSS-induced colon inflammation in mice by regulating intestinal flora.

The application discloses a use of a larazotide polypeptide in preparation of a drug for relieving adriamycin cardiotoxicity. In-vivo experimental results show that the larazotide can effectively relieve the toxic effect of a chemotherapeutic drug adriamycin on the heart, relieve myocardial enzyme spectrum increase, enhance left ventricular diastolic capacity and cardiac ejection fraction by improving body and heart immune cell homeostasis and reducing myocardial tissue cell apoptosis, thereby reducing the toxic side effect of the chemotherapeutic drug adriamycin, and improving intestinal barrier function damage caused by adriamycin chemotherapy. The application overcomes the defects of current clinical drug limitations of Dox and existing chemotherapeutic heart protection drugs, and solves the prevention and treatment problems of heart toxicity and intestinal side effects induced in Dox chemotherapy.

This invention discloses the application of emodin in the preparation of products that inhibit T cell exhaustion. In vitro screening revealed that emodin significantly inhibits T cell exhaustion. Mechanistic studies showed that emodin does not affect Granzyme B secretion, slightly inhibits the secretion level of the cytokine IFN-γ, and significantly reduces the accumulation of protein aggregates within T cells by inhibiting the AKT phosphorylation signaling pathway, thus maintaining cellular protein homeostasis and inhibiting T cell exhaustion. Animal experiments also confirmed that T cells treated with emodin significantly inhibited melanoma growth after adoptive infusion. Therefore, this invention provides the application of emodin in the preparation of products that inhibit T cell exhaustion, further offering a new small-molecule metabolic intervention strategy for improving the efficacy of immunotherapy for solid tumors.

This invention belongs to the field of organic chemistry, specifically providing a class of compounds that can be selectively activated by hypochlorous acid to release hydroxyl groups, along with their preparation methods and applications. These compounds, triggered by HOCl, can efficiently release target molecules containing hydroxyl groups, enabling corresponding treatment, intervention, or functional execution. Simultaneously, these compounds can generate detectable signals such as fluorescence while releasing the charge, allowing for in-situ / real-time monitoring of HOCl levels and the release process in lesion areas, providing a basis for disease assessment and efficacy tracking. These compounds remain relatively inert in normal tissues or when HOCl is at physiological levels, reducing disturbance to HOCl in normal areas and helping to maintain overall HOCl homeostasis and basic immune defense functions. This invention develops a class of compounds that can rapidly respond to hypochlorous acid, release hydroxyl-containing drugs, and monitor disease treatment.